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ABSTRACT
Angiotensin-converting enzyme (ACE) inhibitors modu-
late the function of the renin-angiotensin-aldosterone system, 
and they are commonly prescribed antihypertensive drugs 
especially in patients with renal failure. In this study, the 
relationships between several molecular properties of eight 
ACE inhibitors (enalapril, quinapril, fosinopril, ramipril, 
benazepril, perindopril, moexipril, trandolapril) and their 
renal elimination data, from relevant literature, were in-
vestigated. Th e ’molecular descriptors of the ACE inhibitors, 
which included aqueous solubility data (logS); an electronic 
descriptor, polar surface area (PSA);, a constitutional pa-
rameter, molecular mass (Mr); and a geometric descriptor, 
volume value (Vol), as well as lipophilicity descriptors (logP 
values), were calculated using diﬀ erent software packages. 
Simple linear regression analysis showed the best correlation 
between renal elimination data and lipophilicity descriptor 
AClogP values (R2 = 0.5742). In the next stage of the study, 
multiple linear regression was applied to assess a higher cor-
relation between the ACE inhibitors’ renal elimination data 
and lipophilicity, AClogP, with one additional descriptor as 
an independent variable. Good correlations were established 
between renal elimination data from the literature and the 
AClogP lipophilicity descriptor using the constitutional pa-
rameter (molecular mass (R2 = 0.7425)) or the geometric 
descriptor (volume value (R2 = 0.7224)) as an independent 
variable. Th e application of computed molecular descriptors 
in evaluating drug elimination is of great importance in drug 
research.
Keywords: Angiotensin-converting enzyme inhibitors; 
lipophilicity; molecular mass; elimination.
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SAŽETAK
Inhibitori enzima koji konvertuje angiotenzin (ACE) 
modiﬁ kuju funkciju renin-angiotenzin-aldosteron sistema 
i predstavljaju često propisane lekova za sniženje pritiska, 
posebno kod pacijenata sa insuﬁ cijencijom bubrega. U ovom 
radu, za osam odabranih ACE inhibitora (enalapril, kvi-
napril, fosinopril, ramipril, benazepril, perindopril, moek-
sipril, trandolapril) ispitan je odnos između osobina njihovih 
molekula i njihove eliminacije putem bubrega. Za ispitivane 
inhibitore ACE korišć enjem različitih softverskih paketa 
izračunate su vrednosti nekoliko molekulskih deskriptora: 
rastvorljivost u vodi (logS), elektronski deskriptor – polarna 
površina molekula (PSA), molekulska masa (Mw), geometri-
jski deskriptor – volumen molekula (Vol) kao i deskrip-
tor lipoﬁ lnosti (logP vrednosti). Primenom proste linearne 
regresione analize najbolja zavisnost dobijena je između 
podataka o eliminaciji inhibitora ACE putem bubrega i 
deskriptora lipoﬁ lnosti, AClogP vrednosti (R2 = 0.5742). U 
sledećoj fazi istraživanja primenjena je metoda višestruke 
regresione analize (MLR) kako bi se dobila bolja zavisnost 
između podataka o eliminaciji ACE inhibitora putem bubre-
ga i njihove lipoﬁ lnosti (AClogP vrednosti) uz primenu do-
datnog molekulskog deskriptora kao nezavisno promenljive. 
Dobre korelacije su dobijene između podataka o eliminaciji 
putem bubrega i deskriptora lipoﬁ lnosti AClogP,  uz primenu 
molekulske mase (R2 = 0.7425) ili zapremine molekula (R2 
= 0.7224) kao nezavisno promenljive. Mogućnost primene 
izračunatih molekulskih deskriptora u proceni eliminacije 
lekova je od velikog značaja u njihovom istraživanju.
Ključne reči: Inhibitori enzima koji konvertuje angio-
tenzin; lopoﬁ lnost; molekulska masa; eliminacija.
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INTRODUCTION
Angiotensin-converting enzyme (ACE) inhibitors are 
the most commonly prescribed antihypertensive drugs to-
day. They are a significant group of drugs widely used in 
the treatment of hypertension, congestive heart failure and 
renal failure, especially in patients with diabetes mellitus 
or proteinuria (1).
According their chemical structures, ACE inhibitors 
can be classified into three groups: sulfhydryl-containing 
inhibitors (exemplified by captopril), dicarboxylate-con-
taining (exemplified by enalapril) and phosphonate-con-
taining inhibitors (exemplified by fosinopril). The ACE 
inhibitors are pro-drugs, and, following administration, 
they undergo ester hydrolysis into their active di-acid me-
tabolites, with the exception of lisinopril, which is already 
in the di-acid form (1).
Even though they have the same usage indications, 
they demonstrate differences in their pharmacokinetic and 
pharmacodynamic properties, which may affect their clini-
cal efficacy. The ACE inhibitors demonstrate their antihy-
pertensive effect through their active metabolites by mod-
ulation of the renin-angiotensin-aldosterone enzymatic 
system and selective dilation of efferent renal arterioles. 
In hypertensive patients with renal failure, particularly of 
diabetic aetiology, ACE inhibitors are used as the drug of 
choice because, in addition to their antihypertensive ef-
fects, they slow the progression of microalbuminuria and 
proteinuria (2-5). 
Some ACE inhibitors have dual routes of elimination, 
renal and faecal, which may be important for patients with 
renal failure. They can be applied in patients with end-
stage renal failure who are treated with renal replacement 
therapy, haemo or peritoneal dialysis (1). 
ACE inhibitor’s pharmacological properties (absorp-
tion, protein binding, distribution, activity, duration of 
action and elimination) and their relationship with lipo-
philicity were investigated in numerous studies by chro-
matographic methods, spectrophotometry, capillary elec-
trophoresis or spectrofluorimetry. ACE inhibitors were 
determined in pharmaceutical formulations and biological 
material. There are few data on the elimination of ACE in-
hibitors by peritoneal dialysate (6-17). 
In our previous studies, we investigated the lipophilic-
ity of several ACE inhibitors under different chromato-
graphic conditions (18-20) and the correlation between 
ACE inhibitors’ chromatographic or in silico lipophilicity 
data and with their protein binding (PPB) data (21) or ab-
sorption (22). In continuation of these studies, our aim was 
to correlate ACE inhibitors’ molecular descriptors (elec-
tronic descriptor - polar surface area (PSA); constitutional 
parameter - molecular weight (Mw); geometric descriptor 
- volume value (Vol); aqueous solubility data (logS)) with 
their renal elimination data to determine a reliable rela-
tionship appropriate for evaluating renal elimination of the 
investigated group of drugs. The selection of appropriate 
molecular descriptors was established. 
MATERIALS AND METHODS
The eight most often prescribed ACE inhibitors were 
investigated. 
1. enalapril maleate, (S)-1-[N-[1-(ethoxycarbonyl)-3-
phenylpropyl]-L-alanyl]-L-proline maleate;
2. quinapril hydrochloride, [3S-[2[R*(R*)],3R*]]-
2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-
1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecar-
boxylic acid hydrochloride;
3. fosinopril sodium, (4S)-4-cyclohexyl–1-[[(R)-[(1S)-
2-methyl-1-(1-oxopropoxy)- propoxy](4-phenylbu-
tyl) phosphinyl]acetyl]-L-proline, sodium salt;
4. ramipril, (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-
(ethoxycarbonyl)-3–phenylpropyl]amino]-1–oxo-
propyl] octahydrocyclopenta[b]pyrrole–2–carbox-
ylic acid; 
5. benazepril hydrochloride, (3S)-3-[[1-
(ethoxycarbonyl)-3–phenylpropyl]amino]-2,3,4,5–
tetrahydro–2-oxo–1H-1–benzazepine–1–acetic 
acid hydrochloride; 
6. perindopril erbumin, 2-methylpropan-2-amine 
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-
2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydro-
indole-2-carboxylic acid;
7. moexipril, (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-
4-phenylbutan-2-yl]amino]propanoyl]-6,7-dime-
thoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic 
acid;
8. trandolapril, [2S-[1[R*(R*)],2α,3aα,7aβ]]-1-[2-[[1-
(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopro-
pyl]octahydro-1H-indole-2-carboxylic acid.
The software package Molinspiration Depiction Soft-
ware (Molinspiration Cheminfirmatics) (23) was used for 
the calculation of the electronic descriptor polar surface 
area (PSA), the constitutional parameter molecular weight 
(Mw) and the geometric descriptor volume value (Vol) 
(Table 1). The ACE inhibitors’ lipophilicity descriptors, 
different logP values (AlogPs, AClogP, AB/logP, milogP, 
AlogP, MlogP, KOWWINlogP, XLOGP2, XLOGP3), and 
aqueous solubility data (logS), were calculated using the 
Virtual Computational Chemistry Laboratory software 
package (24). 
The elimination data of the investigated compounds 
(Table 1) were obtained from the relevant literature (1) and 
using software package DrugBank (25). 
Microsoft Excel 2003 and Origin 7.0 PRO (Origin Lab 
Corporation, USA) were used to perform the statistical 
analysis of the regression.
RESULTS 
In this paper, the correlations between renal elimina-
tion data of selected ACE inhibitors and their calculated 
molecular properties were examined. 
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The five molecular descriptors (PSA, Mw, Vol, logP, 
logS) of the ACE inhibitors were calculated using differ-
ent software packages as well as elimination data of inves-
tigated compounds from the relevant literature are shown 
in Table 1. 
In the first stage of the investigation, correlations be-
tween the renal elimination data and calculated molecular 
descriptors of the ACE inhibitors were investigated using 
simple linear regression analysis. The renal elimination 
data and the ’molecular descriptors, (Vol, Mw and logS) 
of the ACE inhibitors showed correlations with correla-
tion coefficients (R2) lower than 0.2. Next, the relationship 
between different lipophilicity descriptors, logP values and 
renal elimination data were examined. The strongest cor-
relation was found between AClogP and the renal elimina-
tion data (R2 = 0.5742). 
Following these results, in the next stage of the study, 
the relationship between renal elimination data and two 
different molecular descriptors of the ACE inhibitors were 
investigated using multiple linear regression (MLR) analy-
sis. The AClogP was chosen as the first independent vari-
able since it showed the best correlations with the ACE 
inhibitors’ renal elimination data. The application of five 
calculated molecular descriptors (PSA, Mw, Vol, logP and 
logS) of ACE inhibitors was investigated by MLR analysis. 
Good correlations were established between renal elim-
ination data obtained from the literature and the AClogP 
lipophilicity descriptor using the constitutional parameter 
molecular mass (R2 = 0.7425) or the geometric descriptor 
volume value (R2 = 0.7224) as an independent variable. The 
values of predicted renal elimination were calculated ac-
cording to the following equations:
Renal el.pred 1 (%) = 101.1189(±48.0996) - 74.9464(±24.0853)AClogP + 
0.3199(±0.1957)Vol 
with n = 8;  R2  = 0.7224; S.D. = 16.6729; F = 6.5073  Eq. 1.
Renal el.pred 2 (%) = 102.1234(±44.0093) - 73.0586(±21.3470)AClogP + 
0.2918(±0.1614)Mw 
with n = 8;  R2  = 0.7425; S.D. = 16.0606; F = 7.2073  Eq. 2.
The results obtained using MLR analysis by applying 
two different descriptors as independent variables are pre-
sented in Table 1 and in Fig. 1. 
DISCUSSION
The clinical success of drugs depends mostly on their 
absorption, distribution, metabolism or route of elimina-
tion (ADME) (26). Lipophilicity is one of the most impor-
tant molecular properties that influence these values, but a 
number of other molecular properties (such as molecular 
ACEi  Ren. el.* AC logP Vol Mw logS PSA Ren. el.A Ren. el.B
1 100 1.52 357 376 -2.92 96 101 101
2 96 2.08 411 439 -3.81 96 77 78
3 50 3.05 539 564 -4.70 110 45 44
4 60 2.07 396 417 -3.58 96 73 72
5 88 2.09 395 424 -4.24 96 71 73
6 100 1.58 358 368 -2.63 96 97 94
7 100 1.87 462 499 -4.21 114 109 111
8 33 2.39 413 430 -3.98 96 54 53
Table 1. Th e ACEi calculated molecular descriptors and renal elimination data collected from relevant literature (*); predicted from (A) AClogP and 
Vol; (B) AClogP and Mw values.
*Ren. El. values obtained from literature (Lemke and Williams, 2013)
Th e numbers denote ACEi.
Fig. 1. Th e relationship between ACEi renal elimination collected from 
relevant literature and (Lemke and Williams, 2013) (Series 1) and pre-
dicted in MLR using AClogP and Vol (Series 2); AClogP and Mw values 
(Series 3). Th e numbers denote ACEi.
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weight (Mw), molecular volume (Vol), polar surface area 
(PSA) and solubility data (logS)) also play important roles 
in drug absorption, tissue penetration, degree of distribu-
tion, degree of plasma protein binding and route of elimi-
nation (27-29). 
According to the available literature, several authors in-
vestigated drugs belonging to the ACE inhibitor group, their 
pharmacological properties and their similarities or differ-
ences (6-10). Their acidity, lipophilicity, solubility and ab-
sorption were evaluated based on their molecular structures 
with the application of computer programs (27-29). 
Various authors have also suggested several assays 
that could be employed in investigations of  different drug 
eliminations (30-32). Most of these methods still have cer-
tain limitations, and a new approach for fast, reliable and 
cost-effective evaluation of the route of elimination of ACE 
inhibitors should be developed. The decrease in complex-
ity and size of the average drug molecule, as well as its low 
logP values and high water solubility, can lead to higher 
probability of drugs being rapidly cleared via renal elimi-
nation (33). Since a drug’s route and degree of elimination 
may affect a drug’s duration of action and activity, the ap-
plication of computed molecular descriptors in the predic-
tion of a drug’s elimination are of great importance, espe-
cially for the newly synthesized drugs. 
In this study, eight ACE inhibitors—,enalapril male-
ate, quinapril hydrochloride, fosinopril sodium, ramipril, 
benazepril hydrochloride, perindopril erbumin, moexipril 
and trandolapril—were studied to evaluate correlations 
between their renal elimination data obtained from the 
relevant literature and calculated molecular descriptors. 
According to the data from the literature, the degree of re-
nal elimination of the ACE inhibitors can vary from 33% 
to 100% (Table 1). The lowest values of renal elimination 
were found for trandolapril (approximately 33%), while 
enalapril, perindopril and moexipril dominantly exhibit re-
nal elimination (approximately 100%). 
The correlations between the ACE inhibitors’ calcu-
lated molecular descriptors and their renal elimination 
data obtained from relevant literature were examined. The 
applicability of calculated molecular descriptors in ACE 
inhibitor elimination evaluation was investigated. The 
main topic of this study was to establish an approach us-
ing simple or multiple linear regression analysis capable of 
predicting the renal elimination of selected ACE inhibitors 
based on their molecular properties.
In the first stage of the study, the relationship between 
all calculated logP values (ClogP, AlogPs, AClogP, AB/
logP, milogP, AlogP, MlogP, KOWWINlogP, XLOGP2, 
XLOGP3) and renal elimination data for ACE inhibitors 
was investigated. Amongst all logP values, only AClogP 
provided a relatively good correlation (R2 = 0.5742) with 
the ’renal elimination data of the ACE inhibitors. 
Second, the relationship between the renal elimination 
data and calculated molecular descriptors of the ACE in-
hibitors was investigated using MLR analysis with appli-
cation of two independent variables, AClogP and one of 
the following: polar surface area (PSA), molecular weight 
(Mw), volume value (Vol) or solubility (logS) to assess their 
higher correlation. The best correlations were established 
between the ACE inhibitors’ renal elimination data and 
the AClogP lipophilicity descriptor using the molecular 
weight (R2 = 0.7425) or volume (R2 = 0.7224) as an indepen-
dent variable, indicating that these molecular properties 
are critical for ACE inhibitors’ route of elimination. The 
established correlations are presented by Eq. 1 and Eq. 2. 
They indicate that the molecule’s lipophilicity has a domi-
nant influence on the ACE inhibitor’s renal elimination, 
and the increase in lipophilicity led to a decrease in their 
renal elimination. 
The correlation observed between the ACE inhibitors’ 
renal elimination data and their in silico molecular descrip-
tors (lipophilicity parameter (AClogP) and constitutional 
parameter (molecular mass) or geometric descriptor (vol-
ume value)) can be considered good, as proposed by Asu-
ero et al. (34), due to the limited number of compounds. 
These correlations confirmed the calculation of descrip-
tors as the technique suitable for evaluation of renal elimi-
nation of the selected compounds. 
CONCLUSION
A relatively good correlation was obtained between 
the renal elimination data and the calculated molecular 
lipophilicity descriptor (AClogP) (R2 = 0.5742). Further-
more, using MLR analysis with two different descriptors 
as independent variables and the lipophilicity descriptor 
(AClogP) and molecular mass or volume value as indepen-
dent variables, better correlations were established (with 
R2 = 0.7425 and R2 = 0.7224, respectively). The possible ap-
plication of computed molecular descriptors in evaluating 
drug routes of elimination can be highly useful in drug re-
search.
The present study may be considered an effective assay 
and could be used as a fast, easy and cost-effective screen-
ing technique for route of elimination evaluation. The pro-
posed methodology confirmed that lipophilicity, together 
with other molecular properties, is essential in a drug’s 
route of elimination.  
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